Comparing two chemo regimens before surgery for low rectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares two chemotherapy combinations given before surgery for low rectal cancer. One group gets a standard chemo pill (CAPOX), while the other gets a more intense combination of three chemo drugs plus an immunotherapy drug (PD-1 inhibitor) to see which approach works better at shrinking tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have rectal cancer that has been confirmed by a biopsy.
- Your tumor must be low in the rectum, within about 2 inches (5 cm) from the anal opening.
- Your cancer must be the type that has not spread beyond the rectum or to nearby lymph nodes.
- You must not have had any prior chemotherapy, radiation, or surgery for this cancer.
- You must be between 18 and 75 years old and be generally healthy enough to undergo treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations given before radiation or surgery for high-risk locally advanced rectal cancer. One arm is more intense, and the other is standard. The goal is to see which works better at shrinking the tumor and possibly avoiding surgery.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
This trial tests whether giving serplulimab (an immune medicine) plus CAPEOX chemotherapy and celecoxib before surgery can shrink locally advanced rectal cancer and improve outcomes. It may help by increasing immune attack on the tumor while chemotherapy helps reduce the cancer before the operation.
This trial tests a combination of three drugs (serplulimab, CAPOX, and bevacizumab) given before surgery to shrink locally advanced rectal cancer. The goal is to make the tumor easier to remove and potentially improve outcomes.
This trial tests a new combination treatment (enverolimab plus standard chemotherapy) given before surgery for very low rectal cancer. The goal is to shrink the tumor so much that patients may avoid surgery and keep their rectum, but the study is for those who haven't had treatment before.
Hear when a new Locally Advanced Low Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.